NEW YORK, March 5 – With $150 million in capital commitments, Applied Genomic Technology Capital Funds has closed its first venture funds, the Cambridge, Mass., venture capital group said Monday.

AGTC Funds, which was founded by venture capital firms NewcoGen and OneLiberty Ventures, plans to finance early-stage genomics companies that focus on information, discoveries, and technology. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.